Title:
【発明の名称】COP-1及びTh-2促進性サイトカインを使用した、多発性硬化症の治療
Document Type and Number:
Japanese Patent JP2002503658
Kind Code:
A
Abstract:
The invention relates to a treatment for multiple sclerosis. COP-1 (copolymer-1), a synthetic polymer consisting of a mixture of random synthetic polypeptides composed of L-alanine, L-glutamic acid, L-lysine and L-tyrosine in a molar ratio of about 6:2:5:1, is administered mucosally to patients afflicted with the disease in combination with Th2 enhancing cytokines such as IL-4 or IL-10. The combination treatment of IL-4 or IL-10 (preferably orally administered) with mucosally administered COP-1 shows a substantially greater suppressive effect than does treatment with cytokine or COP-1 alone.
Inventors:
Howard El Weiner
Ruth Marron
Antony Slavin
Ruth Marron
Antony Slavin
Application Number:
JP2000531442A
Publication Date:
February 05, 2002
Filing Date:
February 12, 1999
Export Citation:
Assignee:
Auto imune ink
International Classes:
A61K9/48; A61K38/00; A61K38/20; A61P25/00; A61P37/06; A61K9/20; (IPC1-7): A61K38/00; A61K9/20; A61K9/48; A61P25/00; A61P37/06
Attorney, Agent or Firm:
Masatake Shiga (7 outside)